The following video is part of our "Motley Fool Conversations" series, in which, Brendan Byrnes, industrials editor/analyst, and David Williamson, health-care editor/analyst, discuss topics across the investing world.
In today's edition, they discuss how Vertex has been beaten down lately as excitement over the next generation of Hep-C treatments has increased concerns that Incivek's blockbuster success will be short-lived. We discuss how the recent planned CEO change will transition the company into more than a one-trick pony. Have a look:
David Williamson and Brendan Byrnes do not own shares of the companies listed above. Motley Fool newsletter services have recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.